sirolimus

(redirected from Rapamune)
Also found in: Medical.

si·ro·li·mus

 (sə-rō′lə-məs)
n.
An immunosuppressive drug produced by the actinomycete Streptomyces hygroscopicus, C15H79NO13, used in combination with cyclosporine and corticosteroids to prevent rejection of transplanted tissues or organs. Also called rapamycin.

[si-, origin unknown + (tac)rolimus.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

sirolimus

n sirolimus m, sirolimús m (INN)
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Sunitinib (sutent), doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and sirolimus (rapamune) are some of the pertinent drugs that are currently available.
However, the results of the drugs attempted were not convincing to warrant their introduction into clinical practice.[14] Previous investigations, including the oral sirolimus to inhibit recurrent in-stent stenosis, oral rapamune to inhibit restenosis, and oral rapamycin to prevent restenosis in Argentina and other studies, evaluated the oral use of sirolimus and reported an average efficacy.
The immunosuppressive regimen consisted of calcineurin inhibitors (sirolimus, rapamune, Phizer, Belgium) in combination with steroids, with or without azathioprine, mycophenolate, or cyclosporine (Sandimmun, Novartis Farma SA, France).
in December 2014, down approximately $1.6 billion in 2015; the loss of exclusivity for Zyvox and Rapamune, as well as the termination of the Spiriva co-promotion collaboration, collectively, down approximately $620 million in 2015; and the performance of Lipitor and BeneFIX, collectively, down approximately $160 million in 2015.
Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.
Immunosuppressive therapy before and after RALP N = 12 Before RALP After RALP A: Calcineurin inhibitors 11/12 * (91.7%) 7/12 (58.3%) (Prograf, Advagraf) B: Corticosteroids 5/12 (41.7%) 4/12 (33.3%) C: Antimetabolite 10/12 (83.3%) 6/12 (50%) (Cellcept) D: mTor inhibitors 0/12 (0%) 8/12 * (66.7%) (Rapamune, Certican) RALP: robot-assisted laparoscopic radical prostatectomy; mTOR: mammalian target of rapamycin.
M2 EQUITYBITES-June 1, 2015-Pfizer awarded first ever landmark approval for RAPAMUNE for rare progressive lung disease Lymphangioleiomyomatosis (LAM)
M2 PHARMA-June 1, 2015-Pfizer awarded first ever landmark approval for RAPAMUNE for rare progressive lung disease Lymphangioleiomyomatosis (LAM)
In the deal, Wyeth, a subsidiary of Pfizer, has agreed to pay $35 million to settle allegations of improper marketing and promotion of the immunosuppressive drug Rapamune. Depending on the number of consumers impacted, states can expect to collect different totals; New York will recover $1.7 million.
A literature search was conducted in MEDLINE and EMBASE via the OVID platform using the key words "interstitial lung disease," "ILD" "interstitial pneumonitis" "pneumonitis" and "alveolar proteinosis" In addition, keywords for the two mTOR inhibitors everolimus and sirolimus were used ("mTOR" "m-TOR" "everolimus" "Certican" "RAD001" "RAD 001" "RAD-001" "sirolimus" "rapamycin" "Rapamune" "AY 22989" "SILA 9268A" "WY-090217" and "proliferation signal inhibitor").
In July, the company paid $491 million to resolve a case of one of its subsidiaries, Wyeth, marketing the drug Rapamune for uses unapproved by the Food and Drug Administration.